Semma Therapeutics
2014
FOUNDED
M&A
STATUS
M&A
LATEST DEAL TYPE
$950M
LATEST DEAL AMOUNT
13
INVESTORS
Description
Developer of trans-formative therapies designed to eliminate the use of insulin injections for type 1 diabetes patients. The company's trans-formative therapies is a cell-based therapy for diabetes which traditionally requires the use of an invasive insulin pump or multiple daily insulin injections combining proprietary cells with a state-of-the-art device to provide a replacement for the missing beta cells in a diabetic patient without immunosuppression, enabling doctors to provide a functional cure for patients with diabetes.
Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 100 Technology Square
- Floor 3
- Cambridge, MA 02139
- United States
+1 (857) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Semma Therapeutics’s full profile, request a free trial.
Semma Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | $950M | 00000 | 00000 | Completed | Generating Revenue | |
| 3. Early Stage VC (Series B) | 30-Nov-2017 | 00000 | 00000 | Completed | Startup | |
| 2. Grant | 12-Sep-2016 | $5M | $44M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 24-Mar-2015 | $44M | $44M | 000.00 | Completed | Startup |
Semma Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Semma Therapeutics Competitors (41)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ViaCyte | Venture Capital-Backed | San Diego, CA | 00 | 00000 | 00000000000 | 00000 |
| 000000000 | Formerly VC-backed | Tucson, AZ | 00 | 000.00 | 000000&0 | 000.00 |
| 00000 | Venture Capital-Backed | Boston, MA | 0 | 0000 | 000 | |
| 0000000000 | Venture Capital-Backed | Abingdon, United Kingdom | 000 | 00000 | 00000000000 | 00000 |
| 00000 000000000000 | Formerly VC-backed | New York, NY | 00 | 000.00 | 000000000000 | 000.00 |
Semma Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 16-Nov-2015 | 000000000000000000 | Therapeutic Devices | 0000000 000000 00.0 |
Semma Therapeutics Executive Team (15)
4 Former Executives
You’re viewing 5 of 15 executives. Get the full list »Semma Therapeutics Board Members (12)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Douglas Melton Ph.D | Semma Therapeutics | Scientific Co-Founder and Board Observer | 000 0000 | |
| Mark Fishman MD | Self | Chairman | 000 0000 |
10 Former Board Members
You’re viewing 2 of 12 board members. Get the full list »